Asahi Songwon cuts Atlas API peak revenue target by two-thirds
Management now sees the combined Chhatral and Atlas units topping out at ₹250-280 cr without new capex, down from the ₹750-800 cr range cited in November 2025.
— 4 earlier stories on Asahi Songwon Colors Ltd. →What's new
- Atlas API peak revenue cut to ₹250-280 cr from ₹750-800 cr over 2-3 years, without new capex.
- European CEP certification for Pregabalin delayed to end-FY27.
- Record-low power costs in blue pigments were a one-time government refund, not sustainable gains.
Why this matters
The Atlas API business was the central growth pillar of Asahi Songwon's narrative. Slashing its peak potential by roughly two-thirds guts the medium-term revenue case. The power-cost clarification also means last quarter's margin performance was inflated by a non-recurring item.
What we're watching
- How the revised revenue ceiling impacts the path to ₹100 cr EBITDA.
- Any update on the Pregabalin European certification beyond the end-FY27 target.
- Whether the company outlines a capex plan to revive the Atlas revenue ambition.
The full read
Asahi Songwon's June 1 concall was a sharp reset. The Atlas API business, which management had pegged at ₹750-800 crore in peak revenue just six months ago, can now only reach ₹250-280 crore without new capital expenditure. That is a roughly two-thirds cut to the core growth story. European CEP certification for Pregabalin, the other potential revenue stream, has been delayed to the end of FY27. Meanwhile, the apparently strong cost performance in blue pigments was a mirage—a one-time government refund. Management still talks about ₹100 crore in EBITDA and ₹1,000 crore in revenue over the long term. The revised Atlas ceiling makes both numbers a far harder climb.
Questions answered
- How much did Asahi Songwon cut its Atlas API revenue outlook?
- Management cut the peak revenue potential for the combined Chhatral and Atlas API units to ₹250-280 crore over the next two to three years. This is down from the ₹750-800 crore range cited in the November 2025 concall.
- Why was the blue pigment business's power cost so low last quarter?
- The record-low power and fuel costs were driven by a one-time government refund, not sustainable operational improvements.
- What is the status of the Pregabalin European certification?
- The timeline for European CEP certification for Pregabalin has been pushed back to the end of the current financial year (FY27). This is a delay from prior expectations.
- Does the company still have its ₹100 crore EBITDA target?
- Management affirmed a target of ₹100 crore in consolidated EBITDA over the medium term and a long-term revenue aspiration of ₹1,000 crore. The revised Atlas outlook makes both numbers a far harder climb.
Story so far
All notes on ASAHISONG →- 1 Jun 2026 · 12:00 PM IST Asahi Songwon cuts Atlas API peak revenue target by two-thirds
- today Asahi Songwon slashes Atlas API peak revenue target to ₹250–280 cr
- 9d ago Asahi Songwon's profit falls 5% on lower revenue in FY26
- 9d ago Asahi Songwon revenue falls 4.8% as founder's son takes the CEO chair
- 9d ago Asahi Songwon passes CEO role to founder's son as revenue slips